Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer

IMMU_TH Press Release

SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech …

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

IMMU_TH Press Release

– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis – – Proceeds of approximately USD 30 million from concurrent financing to fund clinical development pipeline – – Trading to Commence on The Nasdaq Capital Market under Symbol “IMUX” on April 15, 2019 – SAN …

Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10

IMMU_TH Press Release

Listen to the Webcast Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 4:10 pm ET at the Westin Grand Central Hotel, New York. To view the live webcast, please …

Immunic Therapeutics to Participate in Investor and Medical Conferences in March

IMMU_TH Press Release

Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in the following conferences in March: March 6-9: 14th Congress of ECCO (European Crohn’s and Colitis Organization) in Copenhagen. Immunic will host Key Opinion Leader meetings on March 7 and 8. Attending from the company will be Andreas Muehler, …

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

IMMU_TH Press Release

  Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient in a phase 2 clinical study of IMU-838 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by …

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

IMMU_TH Press Release

Listen to the Webcast Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 at 9:45 am ET at the New York Marriott Marquis, in the Chelsea room. To view the live webcast, please follow this link: …

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

IMMU_TH Press Release

Link to Conference Call Webcast Link to Filed Form S-4 (sec.gov)   Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets Lead Program, IMU-838, an Orally Available, Small Molecule Inhibitor of DHODH, Already Advanced into Phase 2 Studies in Ulcerative Colitis  Companies to Host Conference Call to Discuss Transaction at …

Immunic enters into a global option and license agreement with Daiichi Sankyo

IMMU_TH Press Release

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease IMU-856 is a new oral treatment option for ulcerative colitis and Crohn’s disease Daiichi Sakyo Co., Ltd. granted Immunic AG an exclusive option to in-license the drug development program when entering phase 1 clinical development IMU-856 uses an undisclosed new …

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

IMMU_TH Press Release

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor Multiple sites have already been initiated in the US and first patient has been enrolled Several approvals for the ‘CALDOSE-1’ study from regulatory agencies have already been granted in European countries as well and Immunic expects patients to be enrolled in …

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

IMMU_TH Press Release

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will be treated following randomization to multiple doses of IMU-838 or placebo Planegg-Martinsried, Germany, January 11th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, …